In ischemic/reperfusion (I/R) injured hearts, severe oxidative stress occurs and is associated with intracellular calcium (Ca  2+ ) overload. 
Summary
In ischemic/reperfusion (I/R) injured hearts, severe oxidative stress occurs and is associated with intracellular calcium (Ca  2+ ) overload. Glucagon-Like Peptide-1 (GLP-1) analogues have been shown to exert cardioprotection in I/R heart. However, there is little information regarding the effects of GLP-1 analogue on the intracellular Ca 2+ regulation in the presence of oxidative stress. Since the risk of coronary heart disease is increased 2 to 4 times in type-2 diabetic patients (Beckman et al. 2002) , anti-diabetic drugs that are associated with the reduction of cardiovascular events may have beneficial effects for this group of patients. Glucagon-Like Peptide-1 (GLP-1) is an incretin peptide secreting from intestinal L-cells, which has a potent effect on glycemic control (Amori et al. 2007 ). The GLP-1 receptors were expressed in ventricular myocytes (Ban et al. 2008 , Richards et al. 2014 . Liraglutide is one of a long-acting GLP-1 analogue, which has potent glucose lowering effects for treatment of hyperglycemia in type 2 diabetes patients (Amori et al. 2007) . Recent studies demonstrated that GLP-1 analogues exert potent cardioprotective effects in both clinical trials Vol. 66 and animal models (Amori et al. 2007 , Arturi et al. 2016 , Kumarathurai et al. 2016 , Nikolaidis et al. 2005 , Sonne et al. 2008 . In animal models, growing evidence demonstrates the cardioprotective effects of GLP-1 in addition to its glycemic control properties (Nikolaidis et al. 2005) . GLP-1 analogues have been shown to improve cardiac function in ischemic/reperfusion (I/R) injury of porcine model via reduced oxidative stress and increased phosphorylated Akt and Bcl-2 expression (Timmers et al. 2009 ) and activate cytoprotective pathways after I/R injury by modulating the expression and activity of cardioprotective genes including Akt, GSK3beta, PPARbeta-delta, Nrf-2, and HO-1 (Noyan-Ashraf et al. 2009 ). Recent reports also support these basic studies by demonstrating that GLP-1 analogues have exerted potent cardioprotective effects in clinical trials by improved left ventricular ejection fraction, cardiac output, and left ventricular end-diastolic diameter in patients with myocardial infarction and chronic heart failure (Arturi et al. 2016 , Kumarathurai et al. 2016 . Using I/R period, severe oxidative stress occurs and has been shown to be associated with intracellular Ca 2+ overload, thus facilitating both electrical and mechanical dysfunction in the heart (Shintani-Ishida et al. 2012) . Therefore, treatment options which prevent intracellular Ca 2+ overload could potentially be beneficial for I/R hearts. Although currently there is only one study reporting the benefit of GLP-1 on improving intracellular Ca 2+ homeostasis in Hl-1 cells (Huang et al. 2016) This study was approved by the Institutional Animal Care and Use Committee of the Faculty of Medicine, Chiang Mai University. All the animals were fed with normal rat chow and water ad libitum for two weeks prior to experimentation. Male Wistar rats (8-10-week-old, 250-300 g) were used. The rats were deeply anesthetized with thiopental (0.5 mg/kg; Research institute of antibiotics and biotransformations, Roztoky, Czech Republic) after which the hearts were removed for single ventricular myocyte isolation (Palee et al. 2016 , Palee et al. 2013 .
The isolated cardiomyocytes were used in each study protocol for the measurement of intracellular Ca 2+ transient. In the first protocol, cardiomyocytes were divided into 3 groups (n=8 cells/rat and 8 rats/group) as shown in Figure 1A . The real-time Ca 2+ measurements were performed at the beginning of the study (baseline). Then, cardiomyocytes in Group I were treated with normal saline solution (NSS) for 5 min as a control group. Group II's cells were treated with NSS for 2 min and then H 2 O 2 for 3 min to simulate I/R injury. Group III's cells were treated with liraglutide (10 µM) (Novo Nordisk A/S, Denmark) for 5 min. We used liraglutide at a clinically relevant dose; patients receive the maximum clinical dose of 1.8 mg once a day (Margulies et al. 2016) . The concentration we used for an in vitro study in this study was 10 µM of liraglutide which was approximately similar to the dose used in human (Langlois et al. 2016 ).
In the second protocol, cardiomyocytes were divided into 4 groups (n=8 cells/rat and 8 rats/group) as shown in Figure 2A . The real-time Ca 2+ measurements were performed at the beginning of the study (baseline). Then, cardiomyocytes in Group I were treated with NSS for 10 min followed by H 2 O 2 for 3 min as a control group. Group II's cells were treated with NSS for 5 min followed by liraglutide (10 µM) for 5 min and then H 2 O 2 for 3 min. Group III's cardiomyocytes were treated with NSS for 5 min followed by H 2 O 2 for 3 min and then NSS for 5 min as another control group. Group IV were treated with NSS for 5 min followed by H 2 O 2 for 3 min and then liraglutide (10 µM) for 5 min. The real-time Ca 2+ measurements were performed after drug treatment in all groups (Palee et al. 2016) .
In this study, we used H 2 O 2 (50 µM) to induce oxidative stress, to simulate the oxidative stress that is generated by ischemia/reperfusion injury. H 2 O 2 concentration at 50 µM has been widely used to trigger oxidative stress-induced intracellular Ca 2+ dyshomeostasis in cardiomyocytes. H 2 O 2 has been shown to decrease sarco/endoplasmic reticulum Ca 2+ -ATPase (SERCA) and sodium-calcium exchanger (NCX) activities (Huang et al. 2014) by inhibiting protein kinase C (PKC) activities, leading to the alteration of the intracellular Ca 2+ homeostasis (Goldhaber 1996 , Reeves et al. 1986 ). 
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Cardiomyocytes were isolated from the hearts of male Wistar rats using a method described previously (Palee et al. 2016) . In brief, under deep anesthesia, the heart was immediately removed and placed into a modified Langendorff apparatus. The hearts were perfused with modified Krebs solution as previously described (Palee et al. 2016) for 5 min, followed by calcium-free solution (100 μM EGTA) for 4 min, Tyrode's solution with collagenase (0.1 mg/ml) for 10 min, and modified Krebs solution containing 100 μM CaCl 2 and 1 mg/ml type II collagenase for another 8 min. The ventricles were removed from the cannula, cut into small pieces and incubated in 10 ml of collagenase solution gassed with 100 % O 2 for 7 min at 37 °C. A pipette was used to pipette the cell suspension up and down in order to dissociate cardiac tissue into single cells. The cardiomyocytes were separated from undigested ventricular tissues by filtering through cell strainer, and were settling into a loose pellet. Then, the supernatant was removed and replaced with modified Krebs solution containing 1 % BSA and 500 μM CaCl 2 . This process was repeated with modified Krebs solution containing 1 mM CaCl 2 . After this procedure, the cardiomyocytes were ready for recording. (Palee et al. 2013) The isolated cardiomyocytes were placed in a modified Krebs solution containing 1 mM CaCl 2 . Intracellular Ca 2+ transient were measured using the CELL R imaging software (Olympus Soft Imaging Solutions GmbH, Germany). The isolated cardiomyocytes were loaded with Fura-2/AM at a final concentration of 5 µM and fluorescent intensity (excitation wavelengths are 340 nm and 380 nm, and emission wavelength is 510 nm) was recorded during electrical pacing (1 Hz, 10 ms duration, 15 V) (Palee et al. 2016) . The ratio of the emissions wavelengths (510 nm) is directly related to the amount of intracellular Ca
2+
. Data are shown as mean ± SD. Comparisons of variables were performed using the one-way ANOVA followed by LSD post hoc test. P<0.05 was considered statistically significant.
We investigated the effects of liraglutide on intracellular Ca 2+ handling in isolated rat cardiac myocytes exposed to hydrogen peroxide solution to provoke oxidative stress. H 2 O 2 significantly decreased both intracellular Ca 2+ transient amplitude (Fig. 1B) and intracellular Ca 2+ transient decay rate (Fig. 1C) . However, intracellular diastolic Ca 2+ levels were not altered (Fig. 1D) , when compared to the control group (i.e. cardiomyocytes treated with NSS). Moreover, liraglutide (10 µM) significantly increased the intracellular Ca 2+ transient amplitude (Fig. 1B) and Ca 2+ transient decay rate (Fig. 1C) , but did not alter intracellular diastolic Ca 2+ levels (Fig. 1D) , when compared to the control group. The representative Ca 2+ transient tracings are shown in Figure 1E . In the simulated I/R injury protocol, our results demonstrated that cardiomyocytes pretreated with liraglutide significantly increased the intracellular Ca 2+ transient amplitude (Fig. 2B ) and the intracellular Ca 2+ transient decay rate (Fig. 2C ), when compared to the H 2 O 2 treated group. However, in all experimental groups, the levels of intracellular diastolic Ca 2+ levels did not differ (Fig. 2D) . The representative Ca 2+ transient tracings are shown in Figure 2E . Interestingly, we found that when liraglutide was given after H 2 O 2 application to cardiomyocytes, it still significantly increased the intracellular Ca 2+ transient amplitude and intracellular Ca 2+ transient decay rate, when compared to the H 2 O 2 treated group (Fig. 2B, 2C ). Similar to the results of pretreatment, liraglutide given after H 2 O 2 application did not alter the intracellular diastolic Ca 2+ levels.
Since patients with type-2 diabetes mellitus have a higher risk (2 to 4 fold) for developing coronary heart disease including myocardial infarction (Beckman et al. 2002) , anti-diabetic drugs with cardioprotection will be beneficial to these patients. It is known that fatal arrhythmias and LV dysfunction are often observed following acute myocardial infarction (Takamatsu 2008 GLP-1 receptor is expressed in the heart and ventricular myocyte and has a high affinity with a specific GLP-1 receptor agonist liraglutide (Pyke et al. 2014 , Saraiva et al. 2014 . Therefore, in this study the cardioprotective effect of liraglutide is mediated by the GLP-1 receptor dependent pathway via increased phosphorylation of Akt and GSK3β which are involved in the reperfusion injury survival kinase (RISK) pathway (Hausenloy et al. 2005) . This finding was supported by previous studies reported the cardioprotective effects of GLP-1 in animal models (Bose et al. 2005 , Bose et al. 2007 , Kavianipour et al. 2003 , Nikolaidis et al. 2005 . Liraglutide pre-and post-treatment in cardiac I/R injury has been shown to provide cardioprotective effects in both animals and clinical studies , McCormick et al. 2015 , Noyan-Ashraf et al. 2009 , Salling et al. 2012 .
In the present study using , Liu et al. 2016 , Noyan-Ashraf et al. 2009 ).
